Patents by Inventor Yoshiaki MASAKI

Yoshiaki MASAKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220251557
    Abstract: The purpose of the present invention is to reduce the strong hepatotoxicity of antisense nucleic acids that incorporate an artificial nucleobase (e.g., LNA). The present invention provides a bridged antisense nucleic acid for which antisense nucleic acid-induced toxicity is reduced by the supplemental addition to the wing region of a specific artificial nucleobase (e.g., MCA), while retaining the sequence of the antisense nucleic acid and the number of artificial nucleobases (e.g., LNA). The present invention also provides an antisense nucleic acid drug having a remarkably-reduced hepatotoxicity.
    Type: Application
    Filed: November 27, 2020
    Publication date: August 11, 2022
    Applicant: TOKYO INSTITUTE OF TECHNOLOGY
    Inventors: Kohji SEIO, Yoshiaki MASAKI, Takahito TOMORI
  • Patent number: 11384112
    Abstract: Provided is an artificial nucleoside or artificial nucleotide capable of composing an artificial oligonucleotide having superior nuclease resistance. The artificial nucleoside or artificial nucleotide is a compound represented by formula (I) or a salt thereof (wherein, Bx represents a pyrimidine base or purine base, R1, R2, R3 and R4 represent hydrogen atoms, C1-6 alkyl groups or the like, Y represents NR5R6 (wherein, R5 and R6, independently of each other, represent a hydrogen atom, C1-6 alkyl group or the like, or R5 and R6, together with a nitrogen atom bound thereto, form a 3- to 11-membered nitrogen-containing non-aromatic heterocyclic group) or an optionally substituted C2-9 aromatic heterocyclic group, Z1 and Z2 represent hydrogen atoms, hydroxyl group-protecting groups, phosphorous-containing groups or the like, and n represents an integer of 1 to 3).
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: July 12, 2022
    Assignees: TOKYO INSTITUTE OF TECHNOLOGY, NISSAN CHEMICAL CORPORATION
    Inventors: Kohji Seio, Yoshiaki Masaki, Keishi Yamamoto, Keita Yoshida, Yusuke Iriyama, Hiroyuki Nakajima, Tatsuro Kanaki
  • Publication number: 20210188894
    Abstract: Provided is an artificial nucleoside or artificial nucleotide capable of composing an artificial oligonucleotide having superior nuclease resistance. The artificial nucleoside or artificial nucleotide is a compound represented by formula (I) or a salt thereof (wherein, Bx represents a pyrimidine base or purine base, R1, R2, R3 and R4 represent hydrogen atoms, C1-6 alkyl groups or the like, Y represents NR5R6 (wherein, R5 and R6, independently of each other, represent a hydrogen atom, C1-6 alkyl group or the like, or R5 and R6, together with a nitrogen atom bound thereto, form a 3- to 11-membered nitrogen-containing non-aromatic heterocyclic group) or an optionally substituted C2-9 aromatic heterocyclic group, Z1 and Z2 represent hydrogen atoms, hydroxyl group-protecting groups, phosphorous-containing groups or the like, and n represents an integer of 1 to 3).
    Type: Application
    Filed: February 17, 2017
    Publication date: June 24, 2021
    Applicants: TOKYO INSTITUTE OF TECHNOLOGY, NISSAN CHEMICAL CORPORATION
    Inventors: Kohji SEIO, Yoshiaki MASAKI, Keishi YAMAMOTO, Keita YOSHIDA, Yusuke IRIYAMA, Hiroyuki NAKAJIMA, Tatsuro KANAKI
  • Publication number: 20210094980
    Abstract: The present invention relates to a production method and a production intermediate for guanosine-3?,5?-bisdiphosphate.
    Type: Application
    Filed: February 8, 2019
    Publication date: April 1, 2021
    Inventors: Kohji SEIO, Yoshiaki MASAKI, Kentaro OHNO, Takahito TOMORI
  • Publication number: 20210054377
    Abstract: The invention provides an antisense oligonucleotide reduced in toxicity. The antisense oligonucleotide has a central region, a 5?-side region and a 3?-side region, wherein the central region has a nucleotide (2?-3? bridged nucleotide) in which the 2?-position and the 3?-position of a sugar moiety are bridged and/or a non-bridged nucleotide (3?-position-modified non-bridged nucleotide) having a substituent at the 3?-position.
    Type: Application
    Filed: March 20, 2019
    Publication date: February 25, 2021
    Applicants: TOKYO INSTITUTE OF TECHNOLOGY, NISSAN CHEMICAL CORPORATION
    Inventors: Yoshiaki MASAKI, Kohji SEIO, Atsushi INOUE, Yusuke IRIYAMA, Tatsuro KANAKI, Hiroyuki NAKAJIMA